CRB2

Across TCGA pan-cancer cohorts, CRB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRB2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRB2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where CRB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.930	0.607	.001	11	view →
HNSC	OS	Median	All	0.794	0.486	.009	6	view →
PDAC	DFS	Median	All	0.215	0.542	.047	3	view →
GBM	OS	Tertile	All	0.275	0.532	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRB2–CCRCC (DFS)

Open the CCRCC breakdown →